AMDL's Goodnak(R) Anti-Aging Skin Care Line Soon Available in Capsule & Lotion Form
June 24 2008 - 5:10AM
PR Newswire (US)
Easy-to-use formulations help broaden market penetration in China
TUSTIN, Calif., June 24 /PRNewswire-FirstCall/ -- AMDL, Inc.
(AMEX:ADL), (http://www.amdl.com/), a leader in specialty
pharmaceuticals, announced today its subsidiary Jade
Pharmaceutical, Inc. (JPI) anticipates releasing during the 3rd
quarter of 2008 two new formulations of its popular Goodnak(R)
anti-aging skin care product line. In addition to its high quality
injectable formulation, JPI anticipates offering Goodnak in
capsules and an easy-to-apply lotion. Based on general market
information, the proposed pricing for these new formulations will
be approximately US$40.00 per unit, with 60% gross profit margins.
JPI plans to sell both products through existing distribution
channels within the Henan, Sichuan, Guizhou, Shanxi, Xinjiang,
Gansu, Hunnan, Zhejiang, Fujian, Liaoning and Heilongjiang
Provinces of China. Together these regions have a combined
population of more than 376 million people. In addition to China,
AMDL believes both products will be good candidates for export to
the North American and European markets. According to Gary Dreher,
CEO of AMDL, "With the popularity of the Goodnak brand in China,
combined with JPI's ability to sell through pre-approved
distribution channels, we anticipate sales to exceed well beyond
our initial annual sales forecast for Goodnak of $24 million. This
is extremely positive news for the market, Company and our
shareholders." Additional information on AMDL, Goodnak and the
Company's other pharmaceutical products is available at
http://www.amdl.com/. About AMDL: AMDL, Inc. is a global specialty
pharmaceutical Company. The Company is headquartered in Tustin,
California with operations in Shenzhen, Jiangxi, and Jilin, China.
Along with its subsidiary Jade Pharmaceutical Inc. (JPI), AMDL is
devoted to the research, development, manufacture, and marketing of
diagnostic, pharmaceutical, nutritional supplement, and cosmetic
products currently in China. The Company employs approximately 320
people in the U.S. and China. About Jade Pharmaceutical: JPI has
access to the fastest growing pharmaceutical and consumer market in
the world: China. AMDL, through its subsidiaries, Jade currently
manufactures large volume injection fluids, tablets and other
related products, holding licenses for 133 products. It also
manufactures 107 generic, over the counter and supplemental
pharmaceutical products under certified Chinese Good Manufacturing
Practice (CGMP) standards. Forward-Looking Statements This news
release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. Such
statements are subject to certain risks and uncertainties, and
actual circumstances, events or results may differ materially from
those projected in such forward-looking statements. The Company
cautions readers not to place undue reliance on any forward-looking
statements. The Company does not undertake, and specifically
disclaims any obligation, to update or revise such statements to
reflect new circumstances or unanticipated events as they occur.
Contact: Kristine Szarkowitz 206.310.5323 DATASOURCE: AMDL, Inc.
CONTACT: Kristine Szarkowitz, +1-206-310-5323, , for AMDL, Inc. Web
site: http://www.amdl.com/
Copyright
Amdl (AMEX:ADL)
Historical Stock Chart
From May 2024 to Jun 2024
Amdl (AMEX:ADL)
Historical Stock Chart
From Jun 2023 to Jun 2024